Five things for pharma marketers to know: Thursday, March 23, 2017

AHCA set for vote; J&J halts YouTube ads; approval decisions loom for Sanofi, Roche

Drugmakers target severe asthma patients with biologics, but payers raise pricing issue

Biologics prompt asthma marketers to catch their collective breath as innovation has resulted in a rise of payer blockades and sky-high prices

Novartis aims to bring first oral asthma drug to market in two decades

Novartis aims to bring first oral asthma drug to market in two decades

An investigative agent in the Novartis asthma pipeline could give biologics a run for their money.

MM&M's 2017 Agency A-to-Z survey is open

MM&M's 2017 Agency A-to-Z survey is open

The results will be compiled in MM&M's 2017 Agency A-to-Z Directory, the industry's most comprehensive list of healthcare marketing and advertising agencies.

Top 25 respiratory brands, by sales

Top 25 respiratory brands, by sales

While still the top-selling respiratory drug, GSK's Advair is facing growing competition from BI's Spiriva and Roche's Xolair.

Healthgrades' Eric Jensen on providing quality of life

Healthgrades' Eric Jensen on providing quality of life

Healthcare is sometimes about life or death, but is almost always about quality of life, says the EVP of health system products and strategy.

Read the complete March 2017 digital edition

Read the complete March 2017 digital edition

Here you'll find everything you need to know from MM&M's March 2017 issue, including our healthcare marketers trend report, our deep dive into orphan drugs, and more.

The 'i's have it for eye-care brand Xiidra

The 'i's have it for eye-care brand Xiidra

The Xiidra marketing team attempted to move away from the standard drug commercial to shine in a new market and challenge legacy techniques.

Five things for pharma marketers to know: Wednesday, March 22, 2017

Five things for pharma marketers to know: Wednesday, March 22, 2017

Novartis' heart-failure drug fails in clinical trial; Sanofi, Regeneron file Dupixent patent suit; FDA approves Newron's Xadago for PD

Five things for pharma marketers to know: Tuesday, March 21, 2017

Five things for pharma marketers to know: Tuesday, March 21, 2017

Eli Lilly claims it only realizes small percentage of list price increases; PBMs become latest target in pricing backlash; AHCA revised

Low-T DTC ads linked with more testing — and more prescriptions

Low-T DTC ads linked with more testing — and more prescriptions

Researchers found that DTC advertising was associated with significant increases in testing and treatment for these drugs

Five things for pharma marketers to know: Monday, March 20, 2017

Five things for pharma marketers to know: Monday, March 20, 2017

Study finds SGLT-2 inhibitors lowered risk of death; former FDA commissioners raise drug importation issues; Bayer, J&J's Xarelto lowered VTE risk in study

MM&M Startup Showdown connects startups with biopharma execs

MM&M Startup Showdown connects startups with biopharma execs

This program is designed to enable entrepreneurs and biopharma marketers to engage in an intelligent way to explore beyond-the-pill partnerships.

Study finds Repatha reduces risk of heart attack, stroke, but cost concerns remain

Study finds Repatha reduces risk of heart attack, stroke, but cost concerns remain

Amgen said it would offer payers a refund for patients who have a heart attack or stroke while taking the PCSK9 inhibitor.

New healthcare bill to negatively affect drugmakers: Moody's

New healthcare bill to negatively affect drugmakers: Moody's

Per the credit ratings agency, more uninsured Americans will lead to less demand for healthcare services and treatments.

Five things for pharma marketers to know: Friday, March 17, 2017

Five things for pharma marketers to know: Friday, March 17, 2017

The FDA delays final rule related to off-label use; Amgen's Repatha reduces risk of death by 20%, study finds; FDA rejects AstraZeneca's hyperkalaemia drug

Read the complete February 2017 digital edition

Read the complete February 2017 digital edition

Here you'll find everything you need to know from MM&M's February 2017 issue, including our payer state of the union, social media spotlight, and more.

Five things for pharma marketers to know: Thursday, March 16, 2017

Five things for pharma marketers to know: Thursday, March 16, 2017

Marathon to sell Emflaza to PTC Therapeutics; Emma Walmsley's salary is lower than Andrew Witty's; Trump considers Medicare negotiation of drug prices

Industry groups petition the FDA over off-label rule

Industry groups petition the FDA over off-label rule

PhRMA, BIO, and the Medical Information Working Group filed a citizen petition over a final rule they say raises risks for drugmakers.

Roundtable: How healthcare agencies can retain and attract A-list talent

Roundtable: How healthcare agencies can retain and attract A-list talent

Seven execs from A-list agencies weigh in on talent acquisition and retention.

Agency Spotlight

Featured Listings

OPINION

Gottlieb Likely to Take On Off-Label, Predictability at the FDA

Newsletters